Lyell Immunopharma, Inc.LYELNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank33
3Y CAGR-0.1%
5Y CAGR-2.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-0.1%/yr
Annual compound
5Y CAGR
-2.7%/yr
Consistent
Percentile
P33
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive declineStable
PeriodValueYoY Change
TTM$158.68M-7.5%
2024$171.60M-6.2%
2023$182.94M+14.9%
2022$159.19M+14.8%
2021$138.69M-23.9%
2020$182.24M+186.6%
2019$63.59M-